FDA Links Actos® to Bladder Cancer

Millions of Americans have been prescribed products containing the generic form of Actos.

In the Summer of 2011 the FDA issued a warning about the popular diabetes drug Actos (pioglitazone). The FDA had found that the use of pioglitazone for more than a year may be linked to an increased risk of bladder cancer. And recently France and Germany move to restrict use of this drug. The FDA warning was based on a study that shows that an increased risk of bladder cancer was found among patients with the longest exposure to pioglitazone, and in those exposed to the highest cumulative dose of pioglitazone. The warning notes that France and Germany both moved to restrict the use of pioglitazone after a French study linked an increased risk of bladder cancer to long-term use.

Pioglitazone is also a key ingredient in the drugs Actoplus Met, Actoplus Met XR and Duetact. In the first ten months of 2010, more than 2.3 million patients were prescribed a pioglitazone-containing product.

If you or a loved one developed bladder cancer or died after using Actos, you may be entitled to compensation! Call us at 800-862-1260 or complete our quick intake form to receive a FREE case evaluation.